Why the study?
Does telmisartan reduce choroidal neovascularization volume and inflammation in models of age-related macular degeneration?
Does telmisartan reduce choroidal neovascularization volume and inflammation in models of age-related macular degeneration?
AT1-R blockade with telmisartan suppresses choroidal neovascularization through anti-inflammatory and PPAR-gamma-agonistic mechanisms, suggesting a potential novel therapy for age-related macular degeneration.
No takes yet. Share an insight, caveat, or question.
Telmisartan merits human AMD trials; leaves open whether AT1-R blockade reduces CNV clinically.
Nagai et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: